Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04995274 in treatment-resistant depression
NCT03515733Phase 1Completed
- Sponsor
- University of Oxford
- Start
- May 2018
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing PF-04995274 with Placebo (2 arms). Primary endpoints: Facial Expression Recognition Task at Day 7 and Auditory Verbal Learning Task at Day 7. Started May 2018; status: completed.
02
Drugs
PF-04995274
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03515733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03515733.